Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: A comparison of panickers and nonpanickers

Depression and Anxiety

Volumn 8, Issue 1, 1998, Pages 1-7

  Koszycki, Diana ^a   Zacharko, Robert M ^b   Le Mellédo, Jean Michel ^c   Bradwejn, Jacques ^a  

^a ROYAL OTTAWA HOSPITAL   (Canada)

^b CARLETON UNIVERSITY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

ACTH; CCK 4 induced panic; Growth hormone; Prolactin

Indexed keywords

CORTICOTROPIN; GROWTH HORMONE; PROLACTIN; TETRAGASTRIN;

ADULT; ARTICLE; BEHAVIOR; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CONTROLLED STUDY; HORMONE RELEASE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; NEUROENDOCRINOLOGY; PANIC; PRIORITY JOURNAL;

ADOLESCENT; ADRENOCORTICOTROPIC HORMONE; ADULT; AFFECT; ANALYSIS OF VARIANCE; BEHAVIOR; BLOOD PRESSURE; HEART RATE; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; MALE; PANIC; PANIC DISORDER; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; REFERENCE VALUES; TETRAGASTRIN;

EID: 0031713313     PISSN: 10914269     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6394(1998)8:1<1::AID-DA1>3.0.CO;2-G     Document Type: Article

References (32)

1. Abelson JL, Nesse RM, Vinik AI (1994) Pentagastrin infusions in patients with panic disorder. II. Neuroendocrinology. Biol Psychiatry 36:84-96.
2. Aluoja A, Shlik J, Vasar V, Kingisepp PH, Jagomagi K, Vasar E, Bradwejn J (1997) Emotional and cognitive factors associated with response to CCK-4 in healthy volunteers. Psychiatr Res 66:59-67.
3. Bandelow B, Wedekind D, Huther G, Broocks A, Jajak G, Pilz J, Ruther E (1997) Salivary cortisol in panic disorder. Biol Psychiatry 42:285.
4. Biro E, Sarnyai Z, Penke B, Szabo G, Telegdy G (1993) Role of endogenous cortrcotropin-releasing factor in mediation of neuroendocrine and behavioral responses to cholecystokinin octapeptide sulfate in ester rats. Neuroendocrinology 57:340-345.
5. Bradwejn J, Koszycki D (1994) Imipramine antagonism of the panicogenic effects of cholecystokinin-tetrapeptide in panic disorder patients. Am J Psychiatry 151:261-263.
6. Bradwejn J, Koszycki D, Annable L, Couetoux du Tertre A, Reines S, Karkanias C (1992) A dose-ranging study of the behavioral and cardiovascular effects of CCK-4 in patients with panic disorder. Biol Psychiatry 32:903-912.
7. Bradwejn J, Koszycki D, Meterissian G (1990) Cholecystokinin tetrapeptide induces panic attacks in patients with panic disorder. Can J Psychiatry 35:83-85.
8. Bradwejn J, Koszycki D, Shriqui C (1991) Enhanced sensitivity of panic disorder to cholecystokinin-tetrapeptide: Clinical and behavioural results. Arch Gen Psychiatry 48:603-610.
9. Bradwejn J, Koszycki D, Paradis M, Reece P, Hinton J, Sedman A (1995) Effect of CI-988 on cholecystokinin-tetrapepride induced panic symptoms in healthy volunteers. Biol Psychiatry 38:742-746.
10. Bystritsky A, Shapiro D (1992) Continuous physiological changes and subjective reports in panic patients: A preliminary methodological report. Biol Psychiatry 32:766-777.
11. Cameron OG, Lee MA, Curtis GC, McCann DS (1987) Endocrine and physiological changes during spontaneous panic attacks. Psychoneuroendocrinology 12:321-331.
12. de Monrigny C (1989) Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers: preliminary findings. Arch Gen Psychiatry 46:511-517.
13. Degli Uberti EC, Transforini G, Margutti AR, Totola CA, Pansini R (1983) Effect of pentagastrin on adrenocorticotropin hormone and thyroid-stimulating hormone release in normal subjects. Horm Res 17:74-77.
14. Denavit-Saubié M, Hurlé MA, Morin-Surun MP, Boutz AS, Champagnat J (1985) The effects of cholecystokinin-8 in the nucleus tractus solitarius. Ann NY Acad Sci 448:375-384.
15. Flint A, Koszycki D, Vaccarino F, A. Cadieux, Boulenger P, Bradwejn J (1998). The effect of aging on cholecystokinin-induced panic. Am J Psychiatry 155:283-285.
16. Gaffney FA, Fenton BJ, Lane LD, Lake CR (1988) Homodynamic, ventilatory, and biochemical responses of panic patients and normal controls with sodium lactate infusion and spontaneous panic attacks. Arch Gen Psychiatry 45:53-60.
17. Goddard AW, Woods SW, Sholomskas DE, Goodman WK, Charney DS, Heninger GR (1993) Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder. Psychiatr Res 48:119-133.
18. Hollander E, Liebowitz MR, Gorman JM, Cohen B, Fyer A, Klein DF (1989) Cortisol and sodium lactate-induced panic. Arch Gen Psychiatry 46:135-140.
19. Kellner M, Herzog L, Yassouridis A, Holsboer F, Wiedemann K (1995) Possible role of atrial natriuretic hormone in pituitary-adrenocortical unresponsiveness in lactate-induced panic. Am J Psychiatry 152:1365-1367.
20. Kellner M, Yassouridis A, Jahn H, Wiedemann K (1997) Influence of clonidine on psychopathological, endocrine and respiratory-effects of cholecystokinin tetrapeptide in patients with panic disorder. Psychopharmacology 133:55-61.
21. Koszycki D, Cox B, Bradwejn J (1993) Anxiety sensitivity and response to CCK-4 in healthy volunteers. Am J Psychiatry 150:1181-1883.
22. Koszycki D, Zacharko RM, Le Melledo J-M, Young S, Bradwejn J (1996) Effect of acute tryptophan depletion on behavioral, cardiovascular and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers. Biol Psychiatry 40:648-655.
23. Liebowitz MR, Gorman JM, Fyer AJ, Levitt AJ, Dillon M, Levy D, Appleby IL, Anderson S, Palij M, Davies SO, Klein DF (1985) Lactate provocation of panic attacks: II. Biochemical and physiological findings. Arch Gen Psychiatry 41:764-770.
24. McCann UD, Slate SO, Geraci M, Uhde TW (1995) Peptides and anxiety: A dose-response evaluation of pentagastrin in healthy volunteers. Anxiety 1:258-267.
25. McCann UD, Slate SO, Geraci M, Roscow-Terrill D, Uhde TW (1997) A comparison of the effects of intravenous pentagastrin on patients with social phobia, panic disorder and healthy control. Neuropsychopharmacology 16:229-237.
26. Rapee RM (1995) Psychological factors influencing affective response to biological challenge procedures in panic disorder. J Anx Disord 9:59-74.
27. Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J (1997) Effects of citalopram treatment on behavioural, cardiovascular, and neuroendocrine response to cholecystokinin tetrapeptide challenge in panic disorder patients. J Psychiatr Neurosci 22:332-340.
28. Uhde TW, Tancer ME, Rubinow DR, Roscow DB, Boulenger J-P, Vittone B, Gurguis G, Geraci M, Black B, Post RM (1992) Evidence for hypothalamo-growth hormone dysfunction in panic disorder: Profile of growth hormone (GH) response to clonidine, yohimbine, caffeine, glucose, GRF and TRH in panic disorder patients versus healthy volunteers. Neuropsychopharmacology 6:101-118.
29. Van Megan HJGM, Westenberg MGM, den Boer JA, Haigh JRM, Traub M (1994) Pentagastrin induced panic attacks: Enhanced sensitivity in panic disorder. Psychopharmacology 114:449-455.
30. Van Megen HJGM, Westenberg MGM, den Boer JA, Kahn RS (1996) The panic-inducing properties of cholecystokinin tetrapeptide CCK-4 in patients with panic disorder. Eur Neuropsychopharmacol 6:187-194.
31. Van Megan HJGM, Westenberg MGM, den Boer JA (1997) Effect of the selective serotonin reuptake inhibitor fluvoxamine of CCK-4-induced panic attacks. Psychopharmacology 129:357-364.
32. Woods SW, Charney DS, McPherson CA, Gradman AH, Heninger GR (1987) Situational panic attacks: Behavioral, physiologic, and biochemical characterization. Arch Gen Psychiatry 44:365-375.